BQ Blue's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages. These reports offer BloombergQuint's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
As per All Indian Origin Chemists and Distributors Ltd., the Indian Pharma Market (IPM) reported yet another month of decline with 2.2% drop in IPM sales primarily driven by acute segments.
The decline stood at 3.7% for first five months (April-August) of FY21.
We now expect low single digit IPM growth for FY21 with recovery in H2 FY21.
Also expect strong growth in FY22E (double digit growth) on a low base as we believe IPM remains resilient in the current pandemic without any material structural impact.
U.S. generics business has stabilised after few years of consistent decline with stable pricing and faster approvals.
Hence, we remain positive on the sector and expect premium valuations to sustain.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
